MSFT vs ZYME Stock Comparison

Compare MSFT vs ZYME on performance, valuation, growth, fundamentals, momentum and risk; the current AIQ evidence does not show a clear headline leader.

Market data as of Nov 15, 2026 market close· AIQ score gap 0 points
MSFT
Technology
vs
ZYME
Healthcare
MSFT
Microsoft Corporation
Price
$524
Day move
+0.17%
AIQ Score
68/100
Best edge
Risk Resilience
Sector
Technology
ZYME
Zymeworks Inc.
Price
$26.24
Day move
-0.87%
AIQ Score
68/100
Best edge
Value
Sector
Healthcare

What is the main difference between MSFT and ZYME?

MSFT and ZYME are close on the current AIQ evidence, so the better fit depends more on objective, risk tolerance and valuation preference than on a single headline score.

AlgovestIQ AIQ Comparison

Microsoft Corporation vs Zymeworks Inc.

Data as of Nov 15, 2026· market close· Cross-sector · Technology vs Healthcare· Coverage 65/66 fields· High confidence
AIQ VerdictFragileAIQ Comparison Conviction 1/10

MSFT and ZYME are effectively level

MSFT and ZYME are effectively level on the AIQ Score; the factor table below shows where each one holds its advantage.

Evidence agreement: 0 of 6Comparison trend: Weakening
MSFT

Microsoft Corporation

AIQ Score
68/100
AIQ Edge Score
8/10
ZYME

Zymeworks Inc.

AIQ Score
68/100
AIQ Edge Score
8/10

The Algovestiq AIQ Score does not currently separate MSFT and ZYME as of Nov 15, 2026. Both names are scored on the same 0–100 scale across Quality, Value, Momentum and Risk Resilience, and the factor table below shows where each one holds its advantage.

Compare Microsoft Corporation and Zymeworks Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.

Currently unavailable

Performance over time

Total return with distributions reinvested, from daily closes.

MSFT
+60.7%
ZYME
+34.0%

Total return comparison

Growth of $10,000, distributions reinvested

MSFT $16,069 · ZYME $13,401

Split-adjusted closes; each distribution is reinvested at the close on its ex-dividend date. Taxes and trading costs are not modeled.

Compare MSFT and ZYME against another ticker

Open a multi-ticker workspace without changing this focused pair page.

Basic: 2 symbols·Explorer: 3 symbols·Pro and Premium: 5 symbols·Your limit: 2

AIQ Factor Divergence

Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.

MSFT advantage
0
ZYME advantage
  • Value51 vs 66
    ZYME +15
  • Risk Resilience70 vs 61
    MSFT +9
  • Quality65 vs 62
    Even
  • Momentum79 vs 78
    Even

Neither name separates cleanly on the covered dimensions.

What changed since the last close

Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.

MSFT0 AIQ

Largest factor move: Momentum -2, not enough on its own to move the overall score.

No signal started or stopped since the prior session; its 7 active signals are unchanged.

ZYME+2 AIQ

Largest factor move: Risk Resilience +4

New signals

  • Low Volume Rally Warning — bearish, volume, short horizon (0.56x)

MSFT's lead narrowed by 2 AIQ points in the latest session.

Deeper signal detail for each name lives on its own signals page — MSFT and ZYME both carry a full feed there.

Which one fits your objective

The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.

Balanced

Even

Neither separates on the overall score.

Growth

ZYME

ZYME on combined revenue and EPS growth.

Value

ZYME

ZYME on the peer-relative Value factor, by 15 points.

Momentum

Even

The two are level on Momentum.

Lower downside

MSFT

MSFT on Risk Resilience, by 9 points.

Analyst upside

ZYME

ZYME on implied upside to the consensus price target.

AIQ vs Wall Street

Where the systematic read and the analyst consensus line up — and where they do not.

MeasureMSFTZYMENote
Implied upside to target+20.9%+62.3%ZYME has more room
Target dispersion+48.9%+54%Lower is tighter analyst agreement
ConsensusBuyBuyContext, not a primary driver
Analysts covering5814Higher coverage generally improves confidence

Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.

AIQ Agreement Matrix

How each independent group of evidence reads the pair.

Evidence groupFavorsReading
AIQ ScoreEven68 vs 68
FundamentalsZYMEon balancerevenue growth 8.6% vs 54.9%; EPS growth 12.4% vs 4.9%; TTM ROE 8.1% vs 67.3%; gross margin 67.7% vs 98.3%; operating margin 47.1% vs 16.6% — ZYME takes 3 of 5 decided legs, not all of them
ValuationZYMEValue 51 vs 66
TechnicalsMSFTPrice vs 50-day 0.9% vs -4%; vs 200-day 18.7% vs 2.8%
Risk ResilienceMSFTRisk Resilience 70 vs 61
Analyst expectationsZYMETarget upside 20.9% vs 62.3%

AIQ Decision Stability

Fragile

The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.

  • The AIQ gap is narrow at 0 points. (argues the conclusion is provisional)
  • Only 0 of 6 covered evidence groups agree. (argues the conclusion is provisional)
  • The leader's advantage has been narrowing. (argues the conclusion is provisional)
  • The lead has swung materially session to session. (argues the conclusion is provisional)

How the comparison changed

120 daily snapshots · May 27 – Nov 13

MSFT lead: Weakening — the AIQ differential moved from 18 to 0 points over 30 sessions.

May 27MSFT leads above the line · ZYME leads belowNov 13
Today
Level
68 vs 68
7 sessions ago
MSFT +9
68 vs 59
30 sessions ago
MSFT +18
69 vs 51
90 sessions ago
MSFT +12
62 vs 50

The lead changed hands 3 times in this window, most recently on Nov 11 when MSFT moved ahead of ZYME.

AIQ Signal Divergence

Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.

MSFTConflicted

4 bullish / 1 bearish / 2 neutral, conflicted

Only MSFT

  • Bollinger Band Squeeze — neutral, volatility, short horizon (7.6%)
  • OBV Bullish Divergence — bullish, volume, medium horizon (-1.0%)
  • Uptrend Structure Active — bullish, trend, long horizon
ZYMEConflicted

2 bullish / 2 bearish / 2 neutral, conflicted

Only ZYME

  • ATR Expansion - Breakout Mode — neutral, volatility, short horizon (5.44%)
  • Low Volume Rally Warning — bearish, volume, short horizon (0.56x)

Both carry 4 more signals that do not separate them: Golden Cross Active, ADX Trend Weakening, EMA Ribbon Expansion Bullish, MACD Histogram Expanding Bearish.

Price vs model alignment

Whether the latest session's price move confirms what the model did over the same session, or contradicts it.

MSFTNo material change

Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +0.17%, AIQ 0 points).

ZYMEDivergence

Price is down while the AIQ Score moved up 2 points over the same session — price and model disagree (price -0.87%, AIQ +2 points).

The full evidence

Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.

Fundamentals

ZYME leads on balance
MetricMSFTZYME
Revenue growth (YoY)8.6%54.9%
EPS growth (YoY)12.4%4.9%
Gross margin67.7%98.3%
Operating margin47.1%16.6%
Return on equity (TTM)8.1%67.3%
Debt to equity0.282.52

Performance

MSFT leads 4 of 6 windows
MetricMSFTZYME
1 week (5 sessions)-1.3%-11.4%
1 month (20 sessions)-1%4.8%
3 months (63 sessions)9.1%3.7%
6 months (126 sessions)24.2%9.7%
Year to date8.3%-0.3%
1 year (252 sessions)2.5%35.5%

Technicals

MSFT has the stronger structure
MetricMSFTZYME
RSI (14)48.842
ADX (14)1723.8
Price vs 50-day0.9%-4%
Price vs 200-day18.7%2.8%
Volatility (1M, annualized)36.9%63.1%

Risk

MSFT is the more resilient
MetricMSFTZYME
Beta1.020.78
Sharpe ratio0.170.84
Sortino ratio0.261.39
Max drawdown-30.8%-23.6%
Current drawdown-5.7%-16.6%
Annualized volatility34%54%
Value at risk (95%)-2.9%-4.1%

Straight answers

Each answer is regenerated from the current snapshot, not written once and left to age.

Which has more analyst upside, MSFT or ZYME?

Analyst price targets imply +20.9% upside for MSFT and +62.3% for ZYME, so the Street currently favors ZYME. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.

Which is better value, MSFT or ZYME?

ZYME is the better-valued of the two on the peer-relative Value factor. ZYME on the peer-relative Value factor, by 15 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.

Which has stronger growth, MSFT or ZYME?

ZYME on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.

Which has stronger momentum, MSFT or ZYME?

The two are level on Momentum. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.

Which is riskier, MSFT or ZYME?

MSFT is the more resilient of the two, so the other name carries the higher downside risk. MSFT on Risk Resilience, by 9 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.

Is MSFT more profitable than ZYME?

The profitability evidence is mixed: gross margin 67.7% vs 98.3%; operating margin 47.1% vs 16.6%; ttm roe 8.1% vs 67.3%. MSFT leads on one measure and ZYME on two measures, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.

What do the current signals say about MSFT and ZYME?

MSFT: 4 bullish / 1 bearish / 2 neutral, conflicted. ZYME: 2 bullish / 2 bearish / 2 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on MSFT is Golden Cross Active (bullish, long horizon). On ZYME it is Golden Cross Active (bullish, long horizon).

Compare MSFT and ZYME with others

Continue your research

This page answers which of the two. These answer the questions on either side of it.

How this comparison is scored

The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.

The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.

How to use side-by-side comparison →

This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.